All In Biotech

Drug Trial Radar · NCT02626026

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

A Phase 1, Placebo-Controlled, Randomized Study Evaluating the Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)

Last checked: Nov 20, 2026Latest source record: Sep 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

42

Actual

Start

Jan 26, 2016

Primary completion

Sep 1, 2016

Study completion Sep 1, 2016

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Ono Pharmaceutical Co., Ltd.
First posted
Dec 10, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will consist of two parts: Part A will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirabrutinib in healthy participants. Part B will evaluate the safety, tolerability, and the effect of tirabrutinib on disease-specific clinical markers and outcomes in participants with rheumatoid arthritis (RA).

Conditions

  • Rheumatoid Arthritis

Interventions

  • TirabrutinibDrug

    Capsules administered orally.

  • PlaceboDrug

    Capsules administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)Time frame: First dose date up to last dose (maximum: 7 days) plus 30 days
  2. Part A: Percentage of Participants With Treatment-Emergent Laboratory AbnormalitiesTime frame: First dose date up to last dose (maximum: 7 days) plus 30 days
  3. Part A: Percentage of Participants With 12-Lead Electrocardiogram (ECG) AbnormalitiesTime frame: First dose date up to last dose (maximum: 7 days) plus 30 days
  4. Part A: Cmax: Maximum Observed Plasma Concentration of TirabrutinibTime frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
  5. Part A: Clast: Last Observed Quantifiable Plasma Concentration of TirabrutinibTime frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
  6. Part A: Tmax: Time (Observed Time Point) of Cmax of TirabrutinibTime frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
  7. Part A: Tlast: Time (Observed Time Point) of Clast of TirabrutinibTime frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
  8. Part A: AUCtau: Area Under the Plasma Concentration (AUC) Versus Time Curve Over the Dosing Interval of TirabrutinibTime frame: Cohorts 1 and 2, Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose relative to the morning dose
  9. Part A: AUClast: AUC Versus Time Curve From Time Zero to the Last Quantifiable Concentration of TirabrutinibTime frame: Cohorts 1 and 2, Day 1: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, and 24 hours postdose; Day 7: 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36, 48, 60, 72, 96, and 120 hours postdose
  10. Part B: Percentage of Participants Who Experienced TEAEsTime frame: First dose date up to last dose (maximum: 29 days) plus 30 days
  11. Part B: Percentage of Participants With Treatment-Emergent Laboratory AbnormalitiesTime frame: First dose date up to last dose (maximum: 29 days) plus 30 days
  12. Part B: Percentage of Participants With 12-Lead ECG AbnormalitiesTime frame: First dose date up to last dose (maximum: 29 days) plus 30 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • UC Davis Lawrence J. Ellison

    Sacramento, California

  • SeaView Research, Inc.

    Miami, Florida

  • Omega Research Consultants, LLC

    Orlando, Florida

  • Lovelace Scientific Resources, Inc.

    Venice, Florida

  • Center for Arthritis & Osteoporosis

    Elizabethtown, Kentucky

  • Justus J. Fiechtner, M.D., P.C.

    Lansing, Michigan

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania

  • Clinical Research Center of Reading, LLC

    Wyomissing, Pennsylvania

  • Arthritis & Osteoporosis Center of South Texas

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.